265 related articles for article (PubMed ID: 28950886)
21. Role of endogenous 4-1BB in the development of systemic lupus erythematosus.
Vinay DS; Choi JH; Kim JD; Choi BK; Kwon BS
Immunology; 2007 Nov; 122(3):394-400. PubMed ID: 17608689
[TBL] [Abstract][Full Text] [Related]
22. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
23. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S
Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415
[TBL] [Abstract][Full Text] [Related]
25. B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus.
Wen J; Doerner J; Chalmers S; Stock A; Wang H; Gullinello M; Shlomchik MJ; Putterman C
J Neuroinflammation; 2016 Apr; 13(1):73. PubMed ID: 27055816
[TBL] [Abstract][Full Text] [Related]
26. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice.
Stirzaker RA; Biswas PS; Gupta S; Song L; Bhagat G; Pernis AB
Lupus; 2012 May; 21(6):656-61. PubMed ID: 22345122
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of B lymphocyte-induced maturation protein-1 reduces the production of autoantibody and alleviates symptoms of systemic lupus erythematosus.
Luo J; Niu X; Zhang M; Zhang K; Chen M; Deng S
Autoimmunity; 2015 Mar; 48(2):80-6. PubMed ID: 25347333
[TBL] [Abstract][Full Text] [Related]
28. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
[TBL] [Abstract][Full Text] [Related]
29. Pin1-Targeted Therapy for Systemic Lupus Erythematosus.
Wei S; Yoshida N; Finn G; Kozono S; Nechama M; Kyttaris VC; Zhen Zhou X; Tsokos GC; Ping Lu K
Arthritis Rheumatol; 2016 Oct; 68(10):2503-13. PubMed ID: 27159270
[TBL] [Abstract][Full Text] [Related]
30. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice.
Gu F; Molano I; Ruiz P; Sun L; Gilkeson GS
Clin Immunol; 2012 Nov; 145(2):142-52. PubMed ID: 23041504
[TBL] [Abstract][Full Text] [Related]
31. Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice.
Tada Y; Kondo S; Aoki S; Koarada S; Inoue H; Suematsu R; Ohta A; Mak TW; Nagasawa K
Arthritis Rheum; 2011 Mar; 63(3):738-48. PubMed ID: 21305501
[TBL] [Abstract][Full Text] [Related]
32. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
[TBL] [Abstract][Full Text] [Related]
33. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
Bahjat FR; Pine PR; Reitsma A; Cassafer G; Baluom M; Grillo S; Chang B; Zhao FF; Payan DG; Grossbard EB; Daikh DI
Arthritis Rheum; 2008 May; 58(5):1433-44. PubMed ID: 18438845
[TBL] [Abstract][Full Text] [Related]
34. Dissociation of severe lupus-like disease from polyclonal B cell activation and IL 2 deficiency in C3H-lpr/lpr mice.
Davidson WF; Roths JB; Holmes KL; Rudikoff E; Morse HC
J Immunol; 1984 Aug; 133(2):1048-56. PubMed ID: 6610701
[TBL] [Abstract][Full Text] [Related]
35. Mononuclear phagocyte system dysfunction in murine SLE: abnormal clearance kinetics precede clinical disease.
Meryhew NL; Shaver C; Messner RP; Runquist OA
J Lab Clin Med; 1991 Mar; 117(3):181-93. PubMed ID: 2002275
[TBL] [Abstract][Full Text] [Related]
36. TIGIT-Fc fusion protein alleviates murine lupus nephritis through the regulation of SPI-B-PAX5-XBP1 axis-mediated B-cell differentiation.
Zhao J; Li L; Feng X; Gao C; Gao L; Zhan Y; Wang Z; Zhao M; Yin H; Lu Q
J Autoimmun; 2023 Sep; 139():103087. PubMed ID: 37481835
[TBL] [Abstract][Full Text] [Related]
37. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
Front Immunol; 2021; 12():704526. PubMed ID: 34497607
[TBL] [Abstract][Full Text] [Related]
38. Expression of XBP1s in B lymphocytes is critical for pristane-induced lupus nephritis in mice.
Xiang L; Liu A; Xu G
Am J Physiol Renal Physiol; 2020 May; 318(5):F1258-F1270. PubMed ID: 32249615
[TBL] [Abstract][Full Text] [Related]
39. CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice.
Wu X; Guo J; Ding R; Lv B; Bi L
Acta Histochem; 2015 Oct; 117(8):732-7. PubMed ID: 26456520
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Protective Arm of the Renin-Angiotensin System to Reduce Systemic Lupus Erythematosus Related Pathologies in MRL
Soto M; Delatorre N; Hurst C; Rodgers KE
Front Immunol; 2020; 11():1572. PubMed ID: 32793221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
